TNF blockade abolishes the detrimental effect of miR-146a deficiency. (A-B) Allo-HCT was performed as described for the C57BL/6 into BALB/c combination. Recipient mice were treated intraperitoneally with the TNF inhibitor etanercept or vehicle (phosphate-buffered saline) 3 times a week for 4 weeks, starting on day 1. The (A) survival and (B) GVHD histopathology scores of BALB/c recipients are shown. Data were pooled from 2 independent experiments. (C-E) WT or Tnf^−/− T cells were transfected with a miR-146a mimic or a NC mimic, respectively, before transplantation into allogeneic (BALB/c) hosts (2-5 × 10⁵ T cells per mouse). (C) Transfection efficiency was confirmed by qRT-PCR for miR-146a. The (D) survival (n = 10 per group) and (E) GVHD histopathology scores of recipients are shown. ***P < .0001; **P < .01; *P < .05.